Another study in Luminal B [human epidermal growth factor receptor 2 (HER2)-negative] breast cancer identified a residual tumor Ki67 threshold of 23%, above which DFS outcomes were significantly worse (22). This evidence concerns the gene MKI67 and breast carcinoma.